Currently Viewing:
Evidence-Based Oncology Patient-Centered Oncology Care 2016

Immuno‐Oncology Versus Precision Medicine: Where Is Cancer Care Headed?

Surabhi Dangi-Garimella, PhD
At the 5th annual Patient-Centered Oncology Care® meeting, hosted by The American Journal of Managed Care®, experts discussed the contradiction presented by immuno-oncology agents in the world of precision medicine.
FOR DECADES, ADVANCES IN CANCER CARE have struggled with improving patient prognosis and extending survival by weeks or a few months, at most, particularly in patients who may have developed an advanced form of the cancer. The advent of immunotherapy, however, has transformed this picture and has even raised the hope of being able to permanently cure these patients.

At the 5th annual Patient-Centered Oncology Care® meeting, hosted by The American Journal of Managed Care® (AJMC®), November 17-18, 2016, in Baltimore, Joseph Alvarnas, MD, associate professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, engaged experts with diverse experiences and expertise to discuss the contradiction presented by immuno-oncology agents in the world of precision medicine. Alvarnas is also the editor-in-chief of Evidence-Based Oncology™, published by AJMC®.

Joining Alvarnas were David Fabrizio, leader of Cancer Immunotherapy, Foundation Medicine, Inc; Sean Khozin, MD, MPH, senior medical officer, FDA; and David L. Porter, MD, director, Bone Marrow Transplantation, Jodi Fisher Horowitz professor in leukemia care excellence, University of Pennsylvania Health System, Philadelphia.

Alvarnas first asked Fabrizio to share his opinion on how a patient’s genomic information could best be exploited in treatments that utilize the immune system and the strategy that Foundation Medicine was working on to improve the efficiency of immunotherapy to develop a standard practice.

According to Fabrizio, using an assay score comes down to the human interpretation of a qualitative score, which makes it hard to adopt to standard best practices…and leads to genomic solutions. “One such assay is the tumor mutation burden. We do this with CGP [comprehensive genomic profiling] to understand the number of somatic mutations in a person’s cancer genome,” Fabrizio said. CGP, he added, gives an estimate of how the immune system will respond, and the company has been making strides with looking for more unified methods of analysis.

How can we bring standardization to the diagnostic industry? “I think standardization is a huge part of the equation,” Khozin said. CGP, he believes, requires a substantially different approach, one that has not been typically available at large organizations, including the FDA. “Academic institutions have more data mining skills…what we need is a new approach to data science to develop predictive algorithms.” Khozin emphasized the important role of the “omics” approach—proteomics, genomics, the entire microbiome—in patient response to therapy.

Porter added that there have been efforts to integrate omics data in the clinic. “We are looking at biomarkers on T cells. A part of this is committing to and being able to have the right samples and tests,” Porter explained. “We are probably missing huge opportunities right now with our clinical trials; we are banking a lot of samples…DNA, RNA, etc…but we don’t know how to manage them right now, although we will in the future.” He also added that trial design would change in the future and that we may have to settle with smaller and more unique subsets of patients.

Khozin corroborated with Porter that the FDA is looking into such trial designs, as well. “We don’t have to run a large study, rather [we have to] leverage [electronic health record] data that is at the point of care.” The FDA has focused its attention on how care can be advanced, especially with immunotherapy increasingly being a part of the equation. The recently commissioned Oncology Center of Excellence (OCE)1 is working to consolidate oncology functions across the FDA to address the continuum of care in a coherent fashion, Khozin told the audience.



 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!